Please assess the completion status of the following clinical trial:

Trial Title: Octreotide in Severe Polycystic Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age - 18 years and older~* Diagnosis of Polycystic Liver Disease (PLD) associated with ADPKD or isolated Autosomal Dominant Polycystic liver Disease (ADPLD)~* Severe PLD defined as a liver volume greater than 4000 mL or symptomatic disease due to mass effects from hepatic cysts~* Not a candidate for or declining surgical intervention~Exclusion Criteria:~* Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception~* Creatinine greater than 3mg/dL or hemodialysis dependent~* Cancer or major systemic disease that could prevent completion of the planned follow-up or interfere with data collection or interpretation~* Uncontrolled diabetes mellitus as defined by blood glucose levels of greater than or equal to 250 mg/dL on 2 or more consecutive daily readings despite antidiabetic therapy~* Neurologic/psychologic conditions preventing appropriate informed consent~* Symptomatic gallstones or biliary sludge~* Variceal bleeding or hepatic encephalopathy within prior 30 days~* Uncontrolled hypertension (Systolic blood pressure greater than 160 mmHg; Diastolic blood pressure greater than 100 mmHg)~* Current, or prior use of somatostatin analogue (octreotide, lanreotide) in past 6 months~* History of significant adverse reaction to a somatostatin analogue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: ACTIVE_COMPARATOR): Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
- Placebo (Type: PLACEBO_COMPARATOR): Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year

Based on this trial design, predict the completion outcome and termination type (if applicable).